QUESTCAP SIGNS BINDING LOI TO ACQUIRE INTEREST IN AMINO THERAPEUTICS
TORONTO, April 03, 2020 (GLOBE NEWSWIRE) -- QuestCap Inc. (“QuestCap” or the “Company”) (CSE: QSC; OTCMKTS: COPRF; FRA: 34C1) is pleased to announce that the Company has entered into a binding letter of intent (the “LOI”) with Amino Therapeutics, Inc. (“Amino”) to acquire 40% of the issued and outstanding shares of Amino. QuestCap cautions that this is still early stage research and development and is not making any express or implied claims that it has the ability to treat the SARS-CoV-2 virus at this time. Amino has obtained exclusive rights to leverage their parent company’s, Exponential Genomics Inc. (“Xenomics”) XenoArray platform to engineer a potential treatment for COVID-19 (the “Treatment”) based on peptide protease inhibitors. Being developed to engineer to genetically modify multiple microbial strains to produce thousands of peptide-based protease inhibitors in parallel, the XenoArray platform may empower Amino Therapeutics with a unique advantage to potentially design an effective treatment for COVID-19.